Flag of the European Union EU Clinical Trials Register Help

Clinical trials for aml

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    21 result(s) found for: aml. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-002833-10 Sponsor Protocol Number: AML 2004 #069 Start Date*: 2006-03-08
    Sponsor Name:German Competence network “Acute and Chronic Leukemias” sponsored by Federal Ministry of Education a
    Full Title: Curative and palliative treatment of adults aged > 60 years with AML.A randomised trial by OSHO on the role of (1) early intensification {OSHO protocol} vs. common standard arm of German AML Interg...
    Medical condition: Acute myelogenous leukemia
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002430-21 Sponsor Protocol Number: PALOMA Start Date*: 2019-07-17
    Sponsor Name:GWT-TUD GmbH
    Full Title: Primary comparison of Liposomal Anthracycline based treatment versus conventional care strategies prior to allogeneic stem cell transplantation in patients with higher risk MDS and oligoblastic AML
    Medical condition: Untreated patients with higher risk MDS and oligoblastic AML eligible and intended for allogeneic HCT within the next 6 months
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003395-12 Sponsor Protocol Number: ASTX727-02 Start Date*: 2019-11-14
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Mye...
    Medical condition: Acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) CZ (Completed) HU (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003596-30 Sponsor Protocol Number: MEDI4736-MDS-001 Start Date*: 2016-05-23
    Sponsor Name:Celgene International II Sàrl
    Full Title: A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Hi...
    Medical condition: Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) PT (Completed) ES (Ongoing) AT (Completed) DE (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004899-18 Sponsor Protocol Number: LUSPLUS Start Date*: 2021-09-17
    Sponsor Name:GWT-TUD GmbH
    Full Title: A phase IIIb, open-label, single arm study to evaluate the efficacy and safety of luspatercept in patients with lower-risk MDS and ring-sideroblastic phenotype (MDS-RS)
    Medical condition: Lower-risk myelodysplastic syndrome with ring-sideroblastic phenotype (MDS-RS)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028534 Myelodysplastic syndrome NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068361 MDS LLT
    20.0 10005329 - Blood and lymphatic system disorders 10050910 Bone marrow disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000142-34 Sponsor Protocol Number: ITCC-092/IST11028 Start Date*: 2020-09-15
    Sponsor Name:Princess Máxima Center for pediatric oncology
    Full Title: A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML, ITCC-092
    Medical condition: Relapsed or refractory pediatric acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    21.1 100000004864 10081514 Acute myeloid leukemia refractory LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004907-30 Sponsor Protocol Number: AG120-C-009 Start Date*: 2017-09-13
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects ≥ 18 Years of Age with Previously Untreated Acute Myeloid Leukemia w...
    Medical condition: Acute Myeloid Leukemia with an IDH1 Mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Completed) CZ (Completed) NL (Ongoing) FR (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000344-42 Sponsor Protocol Number: AG-221-AML-004 Start Date*: 2016-01-21
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemi...
    Medical condition: Treatment of subjects 60 years or older with acute myeloid leukemia (AML) refractory to or relapsed after second- or third-line AML therapy and positive for an isocitrate dehydrogenase 2 (IDH2) mut...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10060558 Acute myeloid leukemia recurrent LLT
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Completed) BE (Completed) AT (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004603-52 Sponsor Protocol Number: SGI-110-12 Start Date*: 2020-05-20
    Sponsor Name:Astex Pharmaceuticals, Inc.
    Full Title: An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Guadecitabine Clinical Studies
    Medical condition: Acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia (CMML)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) HU (Completed) ES (Ongoing) AT (Completed) FI (Completed) DE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003942-18 Sponsor Protocol Number: ASTX727-06 Start Date*: 2021-09-03
    Sponsor Name:Taiho Oncology, Inc.
    Full Title: An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
    Medical condition: Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009018 Chronic myelomonocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) BG (Trial now transitioned) ES (Completed) LT (Completed) HU (Trial now transitioned) AT (Ongoing) FR (Completed) DE (Trial now transitioned) IT (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004427-38 Sponsor Protocol Number: 0001A3-300-GL Start Date*: 2009-01-28
    Sponsor Name:Antisoma Research Ltd.
    Full Title: Phase 3 Open-Label Randomized Study of Amonafide L-Malate in Combination with Cytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (AML)
    Medical condition: secondary acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Ongoing) AT (Prematurely Ended) HU (Prematurely Ended) EE (Prematurely Ended) CZ (Completed) GB (Prematurely Ended) ES (Prematurely Ended) BE (Completed) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001418-13 Sponsor Protocol Number: TED10893 Start Date*: 2014-11-04
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Phase I Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hemat...
    Medical condition: Haematological malignancy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066476 Haematological malignancy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed) GB (GB - no longer in EU/EEA) FI (Completed) BE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003457-28 Sponsor Protocol Number: CC-486-AML-001 Start Date*: 2013-02-15
    Sponsor Name:Celgene Corporation
    Full Title: A phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subj...
    Medical condition: Acute Myeloid leukemia in complete remission
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000881 Acute myeloid leukaemia (in remission) PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PT (Completed) LT (Completed) IT (Completed) ES (Ongoing) FI (Completed) DE (Completed) AT (Completed) PL (Completed) IE (Completed) GB (GB - no longer in EU/EEA) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004528-40 Sponsor Protocol Number: SY-1425-301 Start Date*: 2021-04-26
    Sponsor Name:Syros Pharmaceuticals, Inc
    Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of SY-1425 Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, RARA-positive Adult Patients with Higher-risk Myelodyspl...
    Medical condition: Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004599-19 Sponsor Protocol Number: INTERFANT-06 Start Date*: 2005-11-24
    Sponsor Name:A.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA
    Full Title: INTERNATIONAL COLLABORATIVE TREATMENT PROTOCOL FOR INFANTS UNDER ONE YEAR WITH ACUTE LYMPHOBLASTIC OR BIPHENOTYPIC LEUKEMIA
    Medical condition: acute lymphoblastic leukemia (ALL) or biphenotypic leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed) FR (Ongoing) DE (Completed) GB (Completed) AT (Ongoing) PT (Completed) DK (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004836-13 Sponsor Protocol Number: BLU-285-2202 Start Date*: 2018-12-29
    Sponsor Name:Blueprint Medicines Corporation
    Full Title: An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Ma...
    Medical condition: Advanced Systemic Mastocytosis (AdvSM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10056453 Aggressive systemic mastocytosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) NO (Completed) DE (Completed) ES (Ongoing) PL (Completed) FR (Completed) AT (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004356-38 Sponsor Protocol Number: M19-388 Start Date*: 2021-08-03
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
    Medical condition: Chronic lymphocytic leukemia; Non-Hodgkin's lymphoma; Multiple Myeloma; T prolymphocytic leukemia; Chronic myeloid leukemia; Waldenstrom's macroglobulinemia lymphoma and Relapsed/refractory pediatr...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009015 Chronic myeloid leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054695 Waldenstrom's macroglobulinemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) PT (Completed) SE (Completed) BE (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-003212-11 Sponsor Protocol Number: ITCC-101/APAL2020D Start Date*: 2022-02-17
    Sponsor Name:Princess Máxima Center
    Full Title: A randomized phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamicin with or without venetoclax in children with relapsed AML
    Medical condition: Children, adolescents, and young adults up to the age of 21 years with acute myeloid leukemia with a documented negative test for FLT3/ITD mutation and either: - Untreated second relapse, who are s...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001941 AML LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) AT (Trial now transitioned) SE (Trial now transitioned) IE (Trial now transitioned) NO (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001466-28 Sponsor Protocol Number: M15-656 Start Date*: 2017-08-07
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia who are Inelig...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Trial now transitioned) FI (Trial now transitioned) SE (Completed) BE (Trial now transitioned) PT (Completed) DK (Completed) CZ (Trial now transitioned) AT (Completed) PL (Completed) FR (Trial now transitioned) ES (Ongoing) HR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003190-34 Sponsor Protocol Number: ACE-536-MDS-002 Start Date*: 2019-01-02
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Ris...
    Medical condition: Myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10068361 MDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) LT (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:05:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA